Total Funding
2
Total FundingDebt Financing raised
Growth Score
pts
Heat Score
-15 pts
Company Performance Metrics
Score
Trend
AI Content may contain mistakes and is not legal, financial or investment advice.Learn more.
Growth Score - The measure of growth based on company activity, operational metrics, and investments
Growth Trend - The change in the growth score over the given time period
Heat Score - The measure of the market interest, media activity, and Crunchbase profile activity
Heat Trend - The change in the heat score over the given time period
See more interactive data and historical milestones on desktop for the best experience
Koronis Pharmaceuticals develops antiviral therapeutics based on a viral decay acceleration mechanism.
John Reno: Chief Operating Officer- John Essigmann: Co-Founder
About the Company
Koronis Pharmaceuticals develops antiviral therapeutics based on a viral decay acceleration mechanism. It is a privately held biotechnology company developing antiviral therapeutics based on a novel mechanism, Viral Decay Acceleration™ (VDA). The Company's lead product candidate is KP-1461 for the treatment of human immunodeficiency virus
(HIV). The Company also has products in development for the treatment of hepatitis C and RSV.
It was founded in 1998 and is based in Seattle, Washington.
